Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6822052 | 0.98 | KDM4E (0.97) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL289685 | 0.89 | KDM4E (0.80) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL27906338 | 0.88 | KDM4E (0.78) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL3065986 | 0.85 | KDM4E (0.73) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL2691717 | 0.85 | KDM4E (0.73) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL23792544 | 0.85 | KDM4E (0.73) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL352098 | 0.81 | KDM4E (0.68) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL25474267 | 0.81 | KDM4E (0.68) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL6786585 | 0.79 | ALDH1A1 (0.63) | KDM4ETDP1L3MBTL1ALDH1A1HDAC1 | |
| SCHEMBL5757892 | 0.77 | KDM4E (0.62) | KDM4ERAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742925-B1 | SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | claimed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | claimed |
| CN-103145711-A | Azaadamantane ester and carbamate derivatives and methods of use thereof | ABBOTT LAB | 2013-06-12 | — | — | CN | claimed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | claimed |
| EP-2129672-B1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-05-18 | — | — | EP | claimed |
| CN-101641355-A | Azaadamantane ester and carbamate derivatives and methods of use thereof | ABBOTT LAB US | 2010-02-03 | — | — | CN | claimed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | claimed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | claimed |
| JP-2007534719-A | — | — | 2007-11-29 | — | — | JP | claimed |
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | GRUENENTHAL GMBH (DE) | 2007-10-25 | — | — | US | claimed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | claimed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| EP-1742925-A1 | SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS | Grünenthal GmbH (DE) | 2007-01-17 | — | — | EP | claimed |
| WO-2005105759-A1 | SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-10 | — | — | WO | claimed |
| US-10398680-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
| US-10272069-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-04-30 | — | — | US | disclosed |
| EP-0262873-B1 | N-TETRAZOLYL THIAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4879295-A | ANTIALLERGENS | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0262873-A1 | N-tetrazolyl thiazolecarboxamide derivatives and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | KDM4E 1441/4885RAB9A 908/4885MEN1 2888/4885 |
| US-10272069-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | KDM4E 3012/4885RAB9A 1131/4885MEN1 4859/4885 |
| US-10398680-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | KDM4E 3012/4885RAB9A 1131/4885MEN1 4859/4885 |
| US-20070249631-A1 | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds | P2RX7, CYP2C8, P2RX5 | KDM4E 2024/4885RAB9A 445/4885MEN1 3500/4885 |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | KDM4E 3012/4885RAB9A 1131/4885MEN1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.